{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:32:01Z","timestamp":1790746321330,"version":"4.1.0"},"reference-count":264,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chronic inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa are systemic conditions marked by persistent immune activation. Growing evidence links them to molecular and vascular ageing, including oxidative stress, endothelial dysfunction, and reduced expression of longevity-related proteins like Klotho and SIRT1. This narrative review examines how Th17- and Th2-driven inflammation contributes to systemic inflammageing. Key cytokines\u2014IL-17, IL-23, IL-4, IL-13, and IL-31\u2014promote endothelial damage, oxidative stress, and metabolic dysfunction. We highlight the role of vascular biomarkers (e.g., VCAM-1, ICAM-1, ST2, P-selectin) and immune cell senescence as indicators of ageing. Finally, we explore whether biologic therapies targeting these pathways may attenuate inflammation-driven ageing. Chronic skin diseases may thus serve as accessible models of systemic inflammageing and targets for early intervention.<\/jats:p>","DOI":"10.3390\/cells14181442","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T16:27:33Z","timestamp":1757953653000},"page":"1442","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Inflammation-Driven Molecular Ageing in Chronic Inflammatory Skin Diseases: Is There a Role for Biologic Therapies?"],"prefix":"10.3390","volume":"14","author":[{"given":"Klara","family":"Andrzejczak","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Sternak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktor","family":"Witkowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"Student Research Group of Experimental Dermatology, University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ponikowska","sequence":"additional","affiliation":[{"name":"Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102540","DOI":"10.1016\/j.arr.2024.102540","article-title":"Immunosenescence and Inflammaging: Mechanisms and Role in Diseases","volume":"101","author":"Ajoolabady","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jacc.2021.12.017","article-title":"Inflammation, Aging, and Cardiovascular Disease","volume":"79","author":"Liberale","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: Molecular Mechanisms and Diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10522-015-9578-8","article-title":"Inflammaging Decreases Adaptive and Innate Immune Responses in Mice and Humans","volume":"17","author":"Frasca","year":"2016","journal-title":"Biogerontology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11357-024-01364-0","article-title":"Inflammation and Aging-Related Disease: A Transdisciplinary Inflammaging Framework","volume":"47","author":"Andonian","year":"2025","journal-title":"Geroscience"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/09546634.2019.1589643","article-title":"Biologics for Chronic Inflammatory Skin Diseases: An Update for the Clinician","volume":"31","author":"Yao","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab Shows Long-Term Safety and Efficacy in Patients with Moderate to Severe Atopic Dermatitis Enrolled in a Phase 3 Open-Label Extension Study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101231","DOI":"10.1016\/j.arr.2020.101231","article-title":"Thymus Involution Sets the Clock of the Aging T-Cell Landscape: Implications for Declined Immunity and Tissue Repair","volume":"65","author":"Elyahu","year":"2021","journal-title":"Ageing Res. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41392-025-02371-z","article-title":"Immunosenescence: Signaling Pathways, Diseases and Therapeutic Targets","volume":"10","author":"Fu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1111\/acel.13671","article-title":"Age-Related Thymic Involution: Mechanisms and Functional Impact","volume":"21","author":"Liang","year":"2022","journal-title":"Aging Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2017-06-746412","article-title":"Aging of Hematopoietic Stem Cells","volume":"131","author":"Lazare","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104698","DOI":"10.1016\/j.exphem.2024.104698","article-title":"Reconsidering the Usual Suspects in Age-Related Hematologic Disorders: Is Stem Cell Dysfunction a Root Cause of Aging?","volume":"143","author":"Fotopoulou","year":"2025","journal-title":"Exp. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.stem.2022.06.012","article-title":"Inflammatory Exposure Drives Long-Lived Impairment of Hematopoietic Stem Cell Self-Renewal Activity and Accelerated Aging","volume":"29","author":"Bogeska","year":"2022","journal-title":"Cell Stem Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Csekes, E., and Ra\u010dkov\u00e1, L. (2021). Skin Aging, Cellular Senescence and Natural Polyphenols. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312641"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2020.11.018","article-title":"Principles of the Molecular and Cellular Mechanisms of Aging","volume":"141","author":"Schumacher","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wagner, K.-H., Cameron-Smith, D., Wessner, B., and Franzke, B. (2016). Biomarkers of Aging: From Function to Molecular Biology. Nutrients, 8.","DOI":"10.3390\/nu8060338"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hwang, H.J., Kim, N., Herman, A.B., Gorospe, M., and Lee, J.-S. (2022). Factors and Pathways Modulating Endothelial Cell Senescence in Vascular Aging. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231710135"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.bbadis.2018.08.008","article-title":"Endothelial Cell Senescence in Aging-Related Vascular Dysfunction","volume":"1865","author":"Jia","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative Stress and Autophagy: The Clash between Damage and Metabolic Needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Liao, Z., Yeo, H.L., Wong, S.W., and Zhao, Y. (2021). Cellular Senescence: Mechanisms and Therapeutic Potential. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121769"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kudlova, N., De Sanctis, J.B., and Hajduch, M. (2022). Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084168"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Yang, Y., Liu, Y., Wang, Y., Chao, Y., Zhang, J., Jia, Y., Tie, J., and Hu, D. (2022). Regulation of SIRT1 and Its Roles in Inflammation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.831168"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111215","DOI":"10.1016\/j.mad.2020.111215","article-title":"SIRT1 and Aging Related Signaling Pathways","volume":"187","author":"Chen","year":"2020","journal-title":"Mech. Ageing Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 Pathway in Parkinson\u2019s Disease: A Faraway Snapshot but so Close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"You, Y., and Liang, W. (2023). SIRT1 and SIRT6: The Role in Aging-Related Diseases. Biochim. Et. Biophys. Acta (BBA)-Mol. Basis Dis., 1869.","DOI":"10.1016\/j.bbadis.2023.166815"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Prud\u2019homme, G.J., Kurt, M., and Wang, Q. (2022). Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations. Front. Aging, 3.","DOI":"10.3389\/fragi.2022.931331"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/36285","article-title":"Mutation of the Mouse Klotho Gene Leads to a Syndrome Resembling Ageing","volume":"390","author":"Matsumura","year":"1997","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1112766","article-title":"Suppression of Aging in Mice by the Hormone Klotho","volume":"309","author":"Kurosu","year":"2005","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: Chronic Inflammation in Ageing, Cardiovascular Disease, and Frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Teissier, T., Boulanger, E., and Cox, L.S. (2022). Interconnections between Inflammageing and Immunosenescence during Ageing. Cells, 11.","DOI":"10.3390\/cells11030359"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., Fourie, A., Fakharzadeh, S., Sherlock, J.P., and Yang, Y.-W. (2024). IL-23 Past, Present, and Future: A Roadmap to Advancing IL-23 Science and Therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1126\/sciimmunol.aau9657","article-title":"Interleukin-17 Receptor D Constitutes an Alternative Receptor for Interleukin-17A Important in Psoriasis-like Skin Inflammation","volume":"4","author":"Su","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_33","first-page":"5160","article-title":"Age-Associated Alteration in Th17 Cell Response Is Related to Endothelial Cell Senescence and Atherosclerotic Cerebral Infarction","volume":"9","author":"Li","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/s41374-021-00629-y","article-title":"Th17\/IL-17 Induces Endothelial Cell Senescence via Activation of NF-\u039aB\/P53\/Rb Signaling Pathway","volume":"101","author":"Zhang","year":"2021","journal-title":"Lab. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2025.04.027","article-title":"Abrocitinib versus Dupilumab: Impact on Skin Barrier Function and Proteomics in Atopic Dermatitis","volume":"93","author":"Chang","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/all.13437","article-title":"The IL-13\/Periostin\/IL-24 Pathway Causes Epidermal Barrier Dysfunction in Allergic Skin Inflammation","volume":"73","author":"Mitamura","year":"2018","journal-title":"Allergy"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A Sensory Neuron-Expressed IL-31 Receptor Mediates T Helper Cell-Dependent Itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-Term Management of Moderate-to-Severe Atopic Dermatitis with Dupilumab and Concomitant Topical Corticosteroids (LIBERTY AD CHRONOS): A 1-Year, Randomised, Double-Blinded, Placebo-Controlled, Phase 3 Trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1080\/09546634.2018.1467536","article-title":"Effects of Etanercept on the Patient-Perceived Results (PROs) in Patients with Moderate-to-Severe Plaque Psoriasis: Systematic Review of the Literature and Meta-Analysis","volume":"29","author":"Carrascosa","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2019.11.062","article-title":"Biological Versus Chronological Aging: JACC Focus Seminar","volume":"75","author":"Hamczyk","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41591-023-02784-9","article-title":"Validation of Biomarkers of Aging","volume":"30","author":"Moqri","year":"2024","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.arr.2018.07.004","article-title":"Towards Frailty Biomarkers: Candidates from Genes and Pathways Regulated in Aging and Age-Related Diseases","volume":"47","author":"Cardoso","year":"2018","journal-title":"Ageing Res. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"117487","DOI":"10.1016\/j.cca.2023.117487","article-title":"ICAM-1 and VCAM-1: Gatekeepers in Various Inflammatory and Cardiovascular Disorders","volume":"548","author":"Singh","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12967-023-04782-4","article-title":"Role of IL-33-ST2 Pathway in Regulating Inflammation: Current Evidence and Future Perspectives","volume":"21","author":"Zhou","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"122701","DOI":"10.1016\/j.lfs.2024.122701","article-title":"Mechanistic Role of RND3-Regulated IL33\/ST2 Signaling on Cardiomyocyte Senescence","volume":"348","author":"Wu","year":"2024","journal-title":"Life Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zinellu, A., and Mangoni, A.A. (2021). Systematic Review and Meta-Analysis of the Effect of Statins on Circulating E-Selectin, L-Selectin, and P-Selectin. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111707"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/09546634.2017.1329498","article-title":"Significant SE-Selectin Levels Reduction after 6 Months of Anti-TNF-\u03b1 Therapy in Non-Diabetic Patients with Moderate-to-Severe Psoriasis","volume":"28","author":"Genre","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood-2017-05-786319","article-title":"Soluble P-Selectin Is the Smoke, Not the Fire","volume":"130","author":"Gross","year":"2017","journal-title":"Blood"},{"key":"ref_49","first-page":"1096","article-title":"[Platelet Activation Marker]","volume":"51","author":"Nomura","year":"2003","journal-title":"Rinsho Byori"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"de la Brassinne Bonardeaux, O., Deneye, M., Oury, C., Moonen, M., and Lancellotti, P. (2025). High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular. J. Clin. Med., 14.","DOI":"10.3390\/jcm14041193"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1381612826666200717090334","article-title":"High Sensitivity C-Reactive Protein (HsCRP) and Its Implications in Cardiovascular Outcomes","volume":"27","author":"Denegri","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3389\/fendo.2020.00560","article-title":"Klotho, Aging, and the Failing Kidney","volume":"11","author":"Buchanan","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kalmykova, A. (2023). Telomere Checkpoint in Development and Aging. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115979"},{"key":"ref_54","first-page":"312","article-title":"Microplate ELISAs for Soluble VCAM-1 and ICAM-1","volume":"35","author":"Chang","year":"2005","journal-title":"Ann. Clin. Lab. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddq061","article-title":"Large-Scale Genomic Studies Reveal Central Role of ABO in SP-Selectin and SICAM-1 Levels","volume":"19","author":"Barbalic","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4103\/0971-5916.166582","article-title":"High Sensitivity C-Reactive Protein (HsCRP) & Cardiovascular Disease: An Indian Perspective","volume":"142","author":"Kamath","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/nprot.2010.124","article-title":"Measurement of Telomere Length by the Southern Blot Analysis of Terminal Restriction Fragment Lengths","volume":"5","author":"Kimura","year":"2010","journal-title":"Nat. Protoc."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1007\/s10072-021-05074-9","article-title":"Plasma Levels of Sirtuin-1 in Patients with Cerebrovascular Stroke","volume":"42","author":"Esmayel","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms Regulating Skin Immunity and Inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Agrawal, R., Hu, A., and Bollag, W.B. (2023). The Skin and Inflamm-Aging. Biology, 12.","DOI":"10.3390\/biology12111396"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive Activation of T(H)2\/T(H)22 Cytokines and Selective Epidermal Proteins Characterizes Acute and Chronic Atopic Dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The Role of the Interleukin-23\/Th17 Pathway in Cardiometabolic Comorbidity Associated with Psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., and Fang, H. (2020). The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12979-025-00500-4","article-title":"The Relationship between Biological Aging and Psoriasis: Evidence from Three Observational Studies","volume":"22","author":"Lin","year":"2025","journal-title":"Immun. Ageing"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The Interleukin 23 Receptor Is Essential for the Terminal Differentiation of Interleukin 17-Producing Effector T Helper Cells in Vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41467-019-08605-3","article-title":"Hectd3 Promotes Pathogenic Th17 Lineage through Stat3 Activation and Malt1 Signaling in Neuroinflammation","volume":"10","author":"Cho","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 Drives a Pathogenic T Cell Population That Induces Autoimmune Inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/030.63.2016.1.1","article-title":"IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways","volume":"63","author":"Behzadi","year":"2016","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1080\/15384101.2019.1653099","article-title":"Skin Immunity and Its Dysregulation in Psoriasis","volume":"18","author":"Lanna","year":"2019","journal-title":"Cell Cycle"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bugaut, H., and Aractingi, S. (2021). Major Role of the IL17\/23 Axis in Psoriasis Supports the Development of New Targeted Therapies. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.621956"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41467-024-44994-w","article-title":"Single-Cell Analysis of Psoriasis Resolution Demonstrates an Inflammatory Fibroblast State Targeted by IL-23 Blockade","volume":"15","author":"Francis","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Brembilla, N.C., Senra, L., and Boehncke, W.-H. (2018). The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01682"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 Immune Axis: From Mechanisms to Therapeutic Testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.immuni.2020.06.022","article-title":"The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24","volume":"53","author":"Chong","year":"2020","journal-title":"Immunity"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbrc.2023.04.079","article-title":"IL-17A Induces Valvular Endothelial Inflammation and Aggravates Calcific Aortic Valve Disease","volume":"672","author":"Yang","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Shen, C.-Y., Lu, C.-H., Wu, C.-H., Li, K.-J., Kuo, Y.-M., Hsieh, S.-C., and Yu, C.-L. (2021). Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis. Cells, 10.","DOI":"10.3390\/cells10123402"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jid.2020.11.006","article-title":"Inflammaging and the Skin","volume":"141","author":"Pilkington","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/CS20100476","article-title":"Aging and Vascular Endothelial Function in Humans","volume":"120","author":"Seals","year":"2011","journal-title":"Clin. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10522-022-09999-2","article-title":"IL-17A Promotes Endothelial Cell Senescence by up-Regulating the Expression of FTO through Activating JNK Signal Pathway","volume":"24","author":"Li","year":"2023","journal-title":"Biogerontology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/fcp.12915","article-title":"Pro-Inflammatory Cytokines Mediating Senescence of Vascular Endothelial Cells in Atherosclerosis","volume":"37","author":"Shang","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Brunner, P.M., Su\u00e1rez-Fari\u00f1as, M., He, H., Malik, K., Wen, H.-C., Gonzalez, J., Chan, T.C.-C., Estrada, Y., Zheng, X., and Khattri, S. (2017). The Atopic Dermatitis Blood Signature Is Characterized by Increases in Inflammatory and Cardiovascular Risk Proteins. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-09207-z"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Pappa, G., Sgouros, D., Theodoropoulos, K., Kanelleas, A., Bozi, E., Gregoriou, S., Krasagakis, K., and Katoulis, A.C. (2022). The IL-4\/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11195633"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4172\/2155-9899.1000110","article-title":"Th2 Cytokines and Atopic Dermatitis","volume":"2","author":"Brandt","year":"2011","journal-title":"J. Clin. Cell Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1021942","DOI":"10.1155\/2016\/1021942","article-title":"IL-4 Gene Polymorphism May Contribute to an Increased Risk of Atopic Dermatitis in Children","volume":"2016","author":"Shang","year":"2016","journal-title":"Dis. Markers"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Olbrich, H., Sadik, C.D., Ludwig, R.J., Tha\u00e7i, D., and Boch, K. (2023). Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules, 13.","DOI":"10.3390\/biom13040634"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic Dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.0901860","article-title":"IL-4 Regulates Skin Homeostasis and the Predisposition toward Allergic Skin Inflammation","volume":"184","author":"Sehra","year":"2010","journal-title":"J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/all.14318","article-title":"Type 2 Immunity in the Skin and Lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-024-02095-4","article-title":"Emerging Biologic Therapies for the Treatment of Atopic Dermatitis","volume":"84","author":"Alvarenga","year":"2024","journal-title":"Drugs"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Junttila, I.S. (2018). Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00888"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a Cytokine Produced by Activated T Cells, Induces Dermatitis in Mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: A New Link between T Cells and Pruritus in Atopic Skin Inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Orfali, R.L., and Aoki, V. (2023). Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020577"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Garcovich, S., Maurelli, M., Gisondi, P., Peris, K., Yosipovitch, G., and Girolomoni, G. (2021). Pruritus as a Distinctive Feature of Type 2 Inflammation. Vaccines, 9.","DOI":"10.3390\/vaccines9030303"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune Interactions in Chronic Itch of Atopic Dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Borgia, F., Custurone, P., Li Pomi, F., Cordiano, R., Alessandrello, C., and Gangemi, S. (2022). IL-31: State of the Art for an Inflammation-Oriented Interleukin. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126507"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: A New Key Player in Dermatology and Beyond","volume":"141","author":"Ruzicka","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.neuroscience.2006.07.009","article-title":"Complete Overlap of Interleukin-31 Receptor A and Oncostatin M Receptor Beta in the Adult Dorsal Root Ganglia with Distinct Developmental Expression Patterns","volume":"142","author":"Bando","year":"2006","journal-title":"Neuroscience"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The Pruritus- and TH2-Associated Cytokine IL-31 Promotes Growth of Sensory Nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jaci.2022.03.010","article-title":"Neuroimmune Communication Regulating Pruritus in Atopic Dermatitis","volume":"149","author":"Steinhoff","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1126\/sciimmunol.abi6887","article-title":"IL-31-Dependent Neurogenic Inflammation Restrains Cutaneous Type 2 Immune Response in Allergic Dermatitis","volume":"8","author":"Fassett","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 Pathway and Its Role in Atopic Dermatitis: A Systematic Review","volume":"28","author":"Saleem","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Yang, G., Seok, J.K., Kang, H.C., Cho, Y.-Y., Lee, H.S., and Lee, J.Y. (2020). Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082867"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Furue, M. (2020). Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155382"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaip.2023.02.005","article-title":"Targeting Skin Barrier Function in Atopic Dermatitis","volume":"11","author":"Elias","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"k1786","DOI":"10.1136\/bmj.k1786","article-title":"Severe and Predominantly Active Atopic Eczema in Adulthood and Long Term Risk of Cardiovascular Disease: Population Based Cohort Study","volume":"361","author":"Silverwood","year":"2018","journal-title":"BMJ"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/jamadermatol.2023.1300","article-title":"Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis","volume":"159","author":"Chen","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s13555-021-00587-9","article-title":"The Use of Real-World Data to Evaluate the Association Between Atopic Dermatitis and Cardiovascular Disease: A Retrospective Claims Analysis","volume":"11","author":"Wu","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.amjmed.2015.05.041","article-title":"Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis","volume":"128","author":"Hjuler","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","article-title":"Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis","volume":"12","author":"Haddad","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting Key Proximal Drivers of Type 2 Inflammation in Disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2023.08.029","article-title":"Systemic Treatments for Atopic Dermatitis (Eczema): Systematic Review and Network Meta-Analysis of Randomized Trials","volume":"152","author":"Chu","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1111\/all.15432","article-title":"Dupilumab Significantly Improves Skin Barrier Function in Patients with Moderate-to-Severe Atopic Dermatitis","volume":"77","author":"Berdyshev","year":"2022","journal-title":"Allergy"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaad.2024.11.079","article-title":"Dupilumab Treatment Restores Lesional and Nonlesional Skin Barrier Function in Adults and Adolescents with Atopic Dermatitis Irrespective of the Filaggrin Genotype: Results from an Open-Label, Healthy-Control-Matched, Phase 4 Clinical Study (BALISTAD)","volume":"92","author":"Bissonnette","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/12034754221130969","article-title":"Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis","volume":"26","author":"Koskeridis","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liu, H., Gao, Y., Sang, H., and Kong, Q. (2025). Effects of Dupilumab on Quality of Life in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1587977"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jdermsci.2018.01.016","article-title":"Dupilumab Treatment in Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"90","author":"Wang","year":"2018","journal-title":"J. Dermatol. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/jdv.19081","article-title":"The Impact of Dupilumab on Skin Barrier Function: A Systematic Review","volume":"37","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab Improves the Molecular Signature in Skin of Patients with Moderate-to-Severe Atopic Dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with Concomitant Topical Corticosteroid Treatment in Adults with Atopic Dermatitis with an Inadequate Response or Intolerance to Ciclosporin A or When This Treatment Is Medically Inadvisable: A Placebo-Controlled, Randomized Phase III Clinical Trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"Smith","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Randomized, Double-Blind, Multicentre, Placebo-Controlled Phase III Trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of Atopic Dermatitis with Tralokinumab, an Anti-IL-13 MAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus Topical Corticosteroids for the Treatment of Moderate-to-Severe Atopic Dermatitis: Results from the Double-Blind, Randomized, Multicentre, Placebo-Controlled Phase III ECZTRA 3 Trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update","volume":"160","author":"Drucker","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized Double-Blinded Placebo-Controlled Phase III Trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials","volume":"24","author":"Thyssen","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and Safety of Lebrikizumab (an Anti-IL-13 Monoclonal Antibody) in Adults with Moderate-to-Severe Atopic Dermatitis Inadequately Controlled by Topical Corticosteroids: A Randomized, Placebo-Controlled Phase II Trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, Ixekizumab, Bimekizumab and Brodalumab for Psoriasis and Psoriatic Arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today (Barc)"},{"key":"ref_135","first-page":"CD011535","article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A Inhibition by Secukinumab Induces Early Clinical, Histopathologic, and Molecular Resolution of Psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/ijd.13236","article-title":"Secukinumab Improves Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling: Results of Two Phase 3, Randomized, Placebo-Controlled Clinical Trials","volume":"55","author":"Strober","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis--Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaad.2017.05.033","article-title":"The Effect of Secukinumab on Moderate-to-Severe Scalp Psoriasis: Results of a 24-Week, Randomized, Double-Blind, Placebo-Controlled Phase 3b Study","volume":"77","author":"Bagel","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab Is Superior to Ustekinumab in Clearing Skin of Subjects with Moderate to Severe Plaque Psoriasis: CLEAR, a Randomized Controlled Trial","volume":"73","author":"Blauvelt","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab Demonstrates Superiority over Narrow-Band Ultraviolet B Phototherapy in New-Onset Moderate to Severe Plaque Psoriasis Patients: Week 52 Results from the STEPIn Study","volume":"37","author":"Iversen","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa (SUNSHINE and SUNRISE): Week 16 and Week 52 Results of Two Identical, Multicentre, Randomised, Placebo-Controlled, Double-Blind Phase 3 Trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-Term Efficacy and Safety of Ixekizumab: A 5-Year Analysis of the UNCOVER-3 Randomized Controlled Trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the Treatment of Patients with Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the 24-Week Randomised, Double-Blind, Placebo-Controlled Period of the SPIRIT-P2 Phase 3 Trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A Head-to-Head Comparison of Ixekizumab vs. Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomized, Double-Blinded Trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"619","DOI":"10.36849\/JDD.8160","article-title":"Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas","volume":"23","author":"Gottlieb","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_149","first-page":"65","article-title":"Clinical Utility of Ixekizumab in the Treatment of Moderate-to-Severe Plaque Psoriasis","volume":"7","author":"Sekhon","year":"2017","journal-title":"Psoriasis (Auckl)"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of Ixekizumab on Psoriasis Itch Severity and Other Psoriasis Symptoms: Results from 3 Phase III Psoriasis Clinical Trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A Head-to-Head Comparison of Ixekizumab vs. Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 12-Week Efficacy, Safety and Speed of Response from a Randomized, Double-Blinded Trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual Neutralization of Both Interleukin 17A and Interleukin 17F with Bimekizumab in Patients with Psoriasis: Results from BE ABLE 1, a 12-Week Randomized, Double-Blinded, Placebo-Controlled Phase 2b Trial","volume":"79","author":"Papp","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis: Two-Year Interim Results from the Open-Label Extension of the Randomized BE RADIANT Phase 3b Trial","volume":"89","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge","volume":"12","author":"Ruggiero","year":"2022","journal-title":"Psoriasis"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00403-025-04174-2","article-title":"The Impact of Biologics Targeting the IL-17 and IL-23 Pathways on Metabolic Indicators in Plaque Psoriasis","volume":"317","author":"Jiang","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-015-0010-2","article-title":"Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis","volume":"2","author":"Savage","year":"2015","journal-title":"Rheumatol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"PHOENIX 1 study investigators Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and Safety of Ustekinumab, a Human Interleukin-12\/23 Monoclonal Antibody, in Patients with Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_162","first-page":"11","article-title":"Ustekinumab: An Evidence-Based Review of Its Effectiveness in the Treatment of Psoriasis","volume":"5","author":"Krulig","year":"2010","journal-title":"Core Evid."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/ced.12390","article-title":"Systematic Review and Meta-Analysis of Ustekinumab for Moderate to Severe Psoriasis","volume":"39","author":"Meng","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_164","first-page":"971","article-title":"Safety and Effectiveness of Ustekinumab for Treatment of Moderate to Severe Psoriasis: A Prospective Study in a Clinical Setting","volume":"13","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies","volume":"34","author":"Strober","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"adv41053","DOI":"10.2340\/actadv.v104.41053","article-title":"Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-Reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial","volume":"104","author":"Errichetti","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bjd.18634","article-title":"Adjusted Treatment COMPArisons between GuSelkumab and UStekinumab for Treatment of Moderate-to-Severe Plaque Psoriasis: The COMPASS Analysis","volume":"183","author":"Diels","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of Clinical Response and Consistent Safety Profile with up to 3 Years of Continuous Treatment with Guselkumab: Results from the VOYAGE 1 and VOYAGE 2 Trials","volume":"82","author":"Reich","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/1744666X.2019.1601014","article-title":"Guselkumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis","volume":"15","author":"Puig","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in Biologic-Naive Patients with Active Psoriatic Arthritis (DISCOVER-2): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the P19 Subunit of Interleukin-23, Through Two\u2009Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and Safety of Guselkumab, an Anti-Interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Treatment of Patients with Moderate to Severe Psoriasis with Randomized Withdrawal and Retreatment: Results from the Phase III, Double-Blind, Placebo- and Active Comparator-Controlled VOYAGE 2 Trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early Disease Intervention with Guselkumab in Psoriasis Leads to a Higher Rate of Stable Complete Skin Clearance (\u2018clinical Super Response\u2019): Week 28 Results from the Ongoing Phase IIIb Randomized, Double-Blind, Parallel-Group, GUIDE Study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and Safety of Risankizumab in Moderate-to-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results from Two Double-Blind, Randomised, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-Term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of the LIMMitless Open-Label Extension Trial up to 5 Years of Follow-Up","volume":"89","author":"Papp","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","article-title":"Targeted Therapies for Patients with Moderate-to-Severe Psoriasis: A Systematic Review and Network Meta-Analysis of PASI Response at 1 Year","volume":"33","author":"Yasmeen","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis (IMMvent): A Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and Safety of Continuous Risankizumab Therapy vs. Treatment Withdrawal in Patients with Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (ReSURFACE 1 and ReSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2310631","DOI":"10.1080\/09546634.2024.2310631","article-title":"Long-Term Quality of Life Outcomes from a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis in a Real-World Setting","volume":"35","author":"Bhatia","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/bjd.19866","article-title":"Five-Year Efficacy and Safety of Tildrakizumab in Patients with Moderate-to-Severe Psoriasis Who Respond at Week 28: Pooled Analyses of Two Randomized Phase III Clinical Trials (ReSURFACE 1 and ReSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"612","DOI":"10.36849\/JDD.8217","article-title":"Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis","volume":"23","author":"Heim","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"2220447","DOI":"10.1080\/09546634.2023.2220447","article-title":"Five-Year Safety of Tildrakizumab in Patients with Moderate-to-Severe Psoriasis from Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2): Number Needed to Harm for Occurrence of Adverse Events of Special Interest","volume":"34","author":"Egeberg","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","article-title":"Tildrakizumab Efficacy, Drug Survival, and Safety Are Comparable in Patients with Psoriasis with and without Metabolic Syndrome: Long-Term Results from 2 Phase 3 Randomized Controlled Studies (ReSURFACE 1 and ReSURFACE 2)","volume":"84","author":"Lebwohl","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/jdv.18167","article-title":"Tildrakizumab Efficacy and Safety in Patients with Psoriasis and Concomitant Metabolic Syndrome: Post Hoc Analysis of 5-Year Data from ReSURFACE 1 and ReSURFACE 2","volume":"36","author":"Fernandez","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3410\/M1-30","article-title":"The Role of TNF Inhibitors in Psoriasis Therapy: New Implications for Associated Comorbidities","volume":"1","author":"Yost","year":"2009","journal-title":"F1000 Med. Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/21645515.2015.1081322","article-title":"A Systematic Review on the Efficacy and Safety of Infliximab in Patients with Psoriasis","volume":"12","author":"Wang","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.2008.08732.x","article-title":"Efficacy and Tolerability of Biologic and Nonbiologic Systemic Treatments for Moderate-to-Severe Psoriasis: Meta-Analysis of Randomized Controlled Trials","volume":"159","author":"Schmitt","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/24755303211047479","article-title":"TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Ma, R., Cui, L., Cai, J., Yang, N., Wang, Y., Chen, Q., Chen, W., Peng, C., Qin, H., and Ding, Y. (2024). Association between Systemic Immune Inflammation Index, Systemic Inflammation Response Index and Adult Psoriasis: Evidence from NHANES. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1111\/all.14859","article-title":"Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis Is Associated with Enhanced Th2 Response","volume":"76","author":"Villani","year":"2021","journal-title":"Allergy"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Visser, M.J.E., Venter, C., Roberts, T.J., Tarr, G., and Pretorius, E. (2021). Psoriatic Disease Is Associated with Systemic Inflammation, Endothelial Activation, and Altered Haemostatic Function. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90684-8"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Zuo, L., Prather, E.R., Stetskiv, M., Garrison, D.E., Meade, J.R., Peace, T.I., and Zhou, T. (2019). Inflammaging and Oxidative Stress in Human Diseases: From Molecular Mechanisms to Novel Treatments. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184472"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2011.04410.x","article-title":"The Concept of Psoriasis as a Systemic Inflammation: Implications for Disease Management","volume":"26","author":"Reich","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jid.2024.09.025","article-title":"The Role and Implications of Epidermal Dysfunction in the Pathogenesis of Inflammaging","volume":"145","author":"Zhang","year":"2025","journal-title":"J. Invest. Dermatol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jaci.2022.12.002","article-title":"Comorbidities of Atopic Dermatitis-What Does the Evidence Say?","volume":"151","author":"Thyssen","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1161\/ATVBAHA.114.304108","article-title":"Interleukin 17 Drives Vascular Inflammation, Endothelial Dysfunction, and Arterial Hypertension in Psoriasis-like Skin Disease","volume":"34","author":"Karbach","year":"2014","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Tsiogka, A., Gregoriou, S., Stratigos, A., Soulaidopoulos, S., Rompoti, N., Panagakis, P., Papoutsaki, M., Kostakis, P., Kontochristopoulos, G., and Tsioufis, K. (2023). The Impact of Treatment with IL-17\/IL-23 Inhibitors on Subclinical Atherosclerosis in Patients with Plaque Psoriasis and\/or Psoriatic Arthritis: A Systematic Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020318"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11845-025-03969-6","article-title":"The Effect of IL-17 and IL-23 Inhibitors on Hematological Inflammatory Parameters in Patients with Psoriasis Vulgaris","volume":"194","year":"2025","journal-title":"Ir. J. Med. Sci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks","volume":"139","author":"Reich","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2024.08.005","article-title":"Dupilumab Reduces Inflammatory Biomarkers in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis","volume":"155","author":"Beck","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual Blockade of IL-4 and IL-13 with Dupilumab, an IL-4R\u03b1 Antibody, Is Required to Broadly Inhibit Type 2 Inflammation","volume":"75","author":"Allinne","year":"2020","journal-title":"Allergy"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"20191123","DOI":"10.1084\/jem.20191123","article-title":"Targeting Interleukin-17 in Chronic Inflammatory Disease: A Clinical Perspective","volume":"217","author":"Zwicky","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.3390\/cimb46070457","article-title":"Inflammatory Cytokines and Clinical Outcome Following Biological Therapy in Adult Bio-Na\u00efve Psoriasis Patients","volume":"46","author":"Florian","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab Progressively Improves Systemic and Cutaneous Abnormalities in Patients with Atopic Dermatitis","volume":"143","author":"Bissonnette","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Singh, R., Koppu, S., Perche, P.O., and Feldman, S.R. (2021). The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312793"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/CIA.S235595","article-title":"Could Inflammaging and Its Sequelae Be Prevented or Mitigated?","volume":"14","author":"Man","year":"2019","journal-title":"Clin. Interv. Aging"},{"key":"ref_211","first-page":"46","article-title":"Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits","volume":"12","author":"Mikhaylov","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of Psoriasis as a Systemic Disease: What Is the Evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","article-title":"Atopic Eczema and Major Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Population-Based Studies","volume":"143","author":"Ascott","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/07853890.2013.870018","article-title":"Atopic Dermatitis and Risk of Ischemic Stroke: A Nationwide Population-Based Study","volume":"46","author":"Su","year":"2014","journal-title":"Ann. Med."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"\u0160ahmatova, L., S\u00fcgis, E., \u0160unina, M., Hermann, H., Prans, E., Pihlap, M., Abram, K., Rebane, A., Peterson, H., and Peterson, P. (2017). Signs of Innate Immune Activation and Premature Immunosenescence in Psoriasis Patients. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-07975-2"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"a041197","DOI":"10.1101\/cshperspect.a041197","article-title":"Aging and Inflammation","volume":"14","author":"Singh","year":"2024","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"e001470","DOI":"10.1136\/rmdopen-2020-001470","article-title":"Inflammaging as a Link between Autoimmunity and Cardiovascular Disease: The Case of Rheumatoid Arthritis","volume":"7","author":"Pizano","year":"2021","journal-title":"RMD Open"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"112163","DOI":"10.1016\/j.exger.2023.112163","article-title":"Biomarkers of the Ageing Immune System and Their Association with Frailty\u2014A Systematic Review","volume":"176","author":"Portielje","year":"2023","journal-title":"Exp. Gerontol."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Hartmann, A., Hartmann, C., Secci, R., Hermann, A., Fuellen, G., and Walter, M. (2021). Ranking Biomarkers of Aging by Citation Profiling and Effort Scoring. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.686320"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Rybtsova, N., Berezina, T., Kagansky, A., and Rybtsov, S. (2020). Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120615"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jamda.2013.05.009","article-title":"Proinflammatory Cytokines, Aging, and Age-Related Diseases","volume":"14","author":"Michaud","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/14397595.2016.1174328","article-title":"Serum Interleukin-6 Levels in Response to Biologic Treatment in Patients with Psoriasis","volume":"27","author":"Muramatsu","year":"2017","journal-title":"Mod. Rheumatol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 Biology into Effective Treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e13628","DOI":"10.1111\/dth.13628","article-title":"High-Sensitivity C-Reactive Protein as a Biomarker in Detecting Subclinical Atherosclerosis in Psoriasis","volume":"33","author":"Niknezhad","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/med.10001","article-title":"Inhibition of LFA-1\/ICAM-1 and VLA-4\/VCAM-1 as a Therapeutic Approach to Inflammation and Autoimmune Diseases","volume":"22","author":"Anderson","year":"2002","journal-title":"Med. Res. Rev."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"864185","DOI":"10.3389\/fmed.2022.864185","article-title":"Endothelial Dysfunction in Psoriasis: An Updated Review","volume":"9","author":"Anyfanti","year":"2022","journal-title":"Front. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.arcmed.2019.05.003","article-title":"Soluble ICAM 1 and VCAM 1 Blood Levels Alert on Subclinical Atherosclerosis in Non Smokers with Asymptomatic Metabolic Syndrome","volume":"50","author":"Varona","year":"2019","journal-title":"Arch. Med. Res."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Zdanowska, N., Owczarczyk-Saczonek, A., Czerwi\u0144ska, J., Nowakowski, J.J., Kozera-\u017bywczyk, A., Owczarek, W., Zdanowski, W., and Placek, W. (2020). Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis. Medicina, 56.","DOI":"10.3390\/medicina56090473"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1136\/ard-2023-224479","article-title":"New Biologic (Ab-IPL-IL-17) for IL-17-Mediated Diseases: Identification of the Bioactive Sequence (NIL-17) for IL-17A\/F Function","volume":"82","author":"Saviano","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5114\/ada.2017.67077","article-title":"Long-Term Treatment of Chronic Plaque Psoriasis with Biological Drugs Can Control Platelet Activation: Targeting the Bridge between Inflammation and Atherothrombosis","volume":"34","author":"Kwiek","year":"2017","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jaad.2009.06.053","article-title":"Platelet Activation in Patients with Psoriasis: Increased Plasma Levels of Platelet-Derived Microparticles and Soluble P-Selectin","volume":"62","author":"Katoh","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1600-0625.2010.01095.x","article-title":"Platelet P-Selectin Reflects a State of Cutaneous Inflammation: Possible Application to Monitor Treatment Efficacy in Psoriasis","volume":"19","author":"Garbaraviciene","year":"2010","journal-title":"Exp. Dermatol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.clim.2009.01.006","article-title":"Platelet-Derived Microparticles and Soluble P-Selectin as Platelet Activation Markers in Patients with Atopic Dermatitis","volume":"131","author":"Katoh","year":"2009","journal-title":"Clin. Immunol."},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Dobric\u0103, E.-C., Cozma, M.-A., G\u0103man, M.-A., Voiculescu, V.-M., and G\u0103man, A.M. (2022). The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants, 11.","DOI":"10.3390\/antiox11020282"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5937\/jomb0-45076","article-title":"Oxidative Stress and Metabolic Biomarkers in Patients with Psoriasis","volume":"43","year":"2024","journal-title":"J. Med. Biochem."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"2249834","DOI":"10.1155\/2022\/2249834","article-title":"Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches","volume":"2022","author":"Medovic","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Bertino, L., Guarneri, F., Cannav\u00f2, S.P., Casciaro, M., Pioggia, G., and Gangemi, S. (2020). Oxidative Stress and Atopic Dermatitis. Antioxidants, 9.","DOI":"10.3390\/antiox9030196"},{"key":"ref_238","first-page":"38","article-title":"The Serum Level of Oxidative Stress and Antioxidant Markers in Patients with Psoriasis: A Cross-Sectional Study","volume":"14","author":"Shakoei","year":"2021","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1179\/1351000213Y.0000000045","article-title":"Altered Redox Status in the Blood of Psoriatic Patients: Involvement of NADPH Oxidase and Role of Anti-TNF-\u03b1 Therapy","volume":"18","author":"Barygina","year":"2013","journal-title":"Redox Rep."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/bjd.12144","article-title":"Oxidative Stress and Psoriasis: The Effect of Antitumour Necrosis Factor-\u03b1 Inhibitor Treatment","volume":"168","author":"Bacchetti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"e12675","DOI":"10.1111\/dth.12675","article-title":"Secukinumab Reduces Plasma Oxidative Stress in Psoriasis: A Case-Based Experience","volume":"31","author":"Becatti","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Medovic, M.V., Milicic, V.M., Nikolic, A.B.R., Ristic, G.J., Medovic, R.H., Nikolic, M.R., Stojanovic, A.Z., Bolevich, S.B., Bondarchuk, N.G., and Gorbunov, A.A. (2024). Effects of Different Therapeutic Approaches on Redox Balance in Psoriatic Patients. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030587"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jaad.2013.06.019","article-title":"Impact of Effective Tumor Necrosis Factor-Alfa Inhibitor Treatment on Arterial Intima-Media Thickness in Psoriasis: Results of a Pilot Study","volume":"69","author":"Szakonyi","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.atherosclerosis.2014.10.008","article-title":"Increased Subclinical Atherosclerosis in Patients with Chronic Plaque Psoriasis","volume":"237","author":"Evensen","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Piros, \u00c9.A., Szab\u00f3, \u00c1., Rencz, F., Brodszky, V., Szalai, K., Galajda, N., Szilveszter, B., D\u00f3sa, E., Merkely, B., and Holl\u00f3, P. (2021). Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-Media Thickness among Severe Psoriatic Patients. Life, 11.","DOI":"10.3390\/life11090919"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/jdv.14841","article-title":"Studying the Effect of Systemic and Biological Drugs on Intima-Media Thickness in Patients Suffering from Moderate and Severe Psoriasis","volume":"32","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/138161282004140213123852","article-title":"Endothelial Dysfunction and the Effects of TNF Inhibitors on the Endothelium in Psoriasis and Psoriatic Arthritis: A Systematic Review","volume":"20","author":"Brezinski","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jdv.12140","article-title":"Circulating Endothelial Cell Levels in Psoriatic Patients and Their Modification after an Anti-TNF-Alpha (Etanercept) Treatment","volume":"28","author":"Caldarola","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"e70642","DOI":"10.1111\/jcmm.70642","article-title":"Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells","volume":"29","author":"Campanati","year":"2025","journal-title":"J. Cell Mol. Med."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mito.2013.01.003","article-title":"Mitochondrial Dysfunction and the Inflammatory Response","volume":"13","year":"2013","journal-title":"Mitochondrion"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2309034","DOI":"10.1155\/2017\/2309034","article-title":"Mitochondrial (Dys) Function in Inflammaging: Do MitomiRs Influence the Energetic, Oxidative, and Inflammatory Status of Senescent Cells?","volume":"2017","author":"Giuliani","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/0394632016662475","article-title":"Expression of Sirtuins 1, 6, Tumor Necrosis Factor, and Interferon-\u03b3 in Psoriatic Patients","volume":"29","author":"Rasheed","year":"2016","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"S\u0142uczanowska-G\u0142abowska, S., Salmanowicz, M., Staniszewska, M., and Pawlik, A. (2023). The Role of Sirtuins in the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310782"},{"key":"ref_254","first-page":"157","article-title":"Abnormal Expression of SIRTs in Psoriasis: Decreased Expression of SIRT 1-5 and Increased Expression of SIRT 6 and 7","volume":"44","author":"Fan","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Bielach-Bazyluk, A., Zbroch, E., Mysliwiec, H., Rydzewska-Rosolowska, A., Kakareko, K., Flisiak, I., and Hryszko, T. (2021). Sirtuin 1 and Skin: Implications in Intrinsic and Extrinsic Aging-A Systematic Review. Cells, 10.","DOI":"10.3390\/cells10040813"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1159\/000343318","article-title":"SIRT1 Regulates CD40 Expression Induced by TNF-\u03b1 via NF-\u0138B Pathway in Endothelial Cells","volume":"30","author":"Yang","year":"2012","journal-title":"Cell Physiol. Biochem."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/156652413804486223","article-title":"SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases","volume":"13","author":"Wang","year":"2013","journal-title":"Curr. Mol. Med."},{"key":"ref_258","doi-asserted-by":"crossref","unstructured":"Prud\u2019homme, G.J., and Wang, Q. (2024). Anti-Inflammatory Role of the Klotho Protein and Relevance to Aging. Cells, 13.","DOI":"10.20944\/preprints202408.0213.v1"},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Wen, Z., Liu, X., and Zhang, T. (2024). L-Shaped Association of Systemic Immune-Inflammation Index (SII) with Serum Soluble \u03b1-Klotho in the Prospective Cohort Study from the NHANES Database. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64050-3"},{"key":"ref_260","doi-asserted-by":"crossref","unstructured":"Hajare, A.D., Dagar, N., and Gaikwad, A.B. (2025). Klotho Antiaging Protein: Molecular Mechanisms and Therapeutic Potential in Diseases. Mol. Biomed., 6.","DOI":"10.1186\/s43556-025-00253-y"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.amjms.2020.10.021","article-title":"Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases","volume":"361","author":"Russell","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","article-title":"Psoriatic Skin Molecular and Histopathologic Profiles after Treatment with Risankizumab versus Ustekinumab","volume":"143","author":"Visvanathan","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Bellinato, F., Chiricozzi, A., Piaserico, S., Targher, G., and Gisondi, P. (2022). Could Targeted Pharmacotherapies Exert a \u201cDisease Modification Effect\u201d in Patients with Chronic Plaque Psoriasis?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112849"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The Translational Revolution in Atopic Dermatitis: The Paradigm Shift from Pathogenesis to Treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol. Immunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/18\/1442\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:45:55Z","timestamp":1760035555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/18\/1442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":264,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cells14181442"],"URL":"https:\/\/doi.org\/10.3390\/cells14181442","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]}}}